BiomX Inc. 8-K

What Happened

• BiomX Inc. (PHGE) filed an 8-K on June 5, 2026 disclosing that it issued 1,013,637 restricted shares of common stock to three assignees upon partial conversion of a convertible promissory note originally held by Mandragola Ltd. The conversion represented about $379,000 of principal.
• On May 13, 2026 the company and Mandragola entered a Line of Credit Agreement providing a revolving credit line of up to $2,000,000. Each advance is evidenced by a 12% simple annual interest convertible promissory note convertible at the prior trading day's closing price. As additional consideration, BiomX issued Mandragola a five‑year warrant to buy up to 2,000,000 shares at $12.00 per share (cashless exercise; subject to NYSE American stockholder approval).

Key Details

• Shares issued on conversion: 1,013,637 restricted shares to three assignees (conversion of ~$379,000 principal).
• Post-issuance shares outstanding: 11,160,153 common shares.
• Credit line: up to $2,000,000; advances bear 12% simple annual interest and are convertible into common stock at market price.
• Warrant: five-year warrant for up to 2,000,000 shares at $12.00/share, cashless exercise; warrants issued in reliance on Section 4(a)(2) and exercise shares subject to stockholder approval.

Why It Matters

• Financing and liquidity: the $2M credit line gives BiomX immediate financing flexibility but at a relatively high 12% interest rate and with conversion features that can increase equity dilution.
• Dilution risk: shareholders should note the immediate increase in outstanding shares and potential further dilution from convertible notes and the 2,000,000‑share warrant if exercised.
• Registration status: the Conversion Shares and the warrant were issued without registration (relying on Section 4(a)(2)), and the Conversion Shares are restricted—investors cannot freely trade them without registration or an exemption.